secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001384101-22-000105
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q2 revenue $72.9M (+32% YoY); net loss $9.5M, EPS -$0.13
-----------------------------------------------------------------

- Revenue $72.9M, +32% YoY; testing $59.7M (+18%), biopharma $10.0M (vs $1.6M).
- Test volume 24,904, +19% YoY; GAAP gross margin 59%, non-GAAP 66%.
- Net loss $9.5M (+5% YoY), EPS -$0.13; non-GAAP op expenses $49.0M.
- Cash and investments $164.0M at June 30; operating cash flow improved $29.4M YTD.
- AUA/ASRO guideline now favorable for Decipher Prostate; multiple clinical data presentations at ASCO, ENDO, ESMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410122000105/0001384101-22-000105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410122000105/vcyt-20220802.htm
  HTML page:      https://secwatch.observer/filing/0001384101-22-000105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer